Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.

Leukemia·2017
Same author

Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.

Leukemia·2017
Same author

Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.

Klinische Padiatrie·2015
Same author

Consensus of German transplant centers on hematopoietic stem cell transplantation in Fanconi anemia.

Klinische Padiatrie·2015
Same author

Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.

Leukemia·2015

Related Experiment Videos

[Systemic therapy in children and adolescents].

B Kremens1

  • 1Klinik für Kinderheilkunde 3,Hämatologie, Onkologie, Pulmologie, Zentrum für Kinder- und Jugendmedizin,Universitätsklinikum, 45122 Essen. bernhard.kremens@uni-due.de

Der Urologe. Ausg. A
|September 8, 2007
PubMed
Summary

Pediatric urologic cancers like nephroblastoma and neuroblastoma have high survival rates with standard German treatment studies. Multimodal therapy, including chemotherapy, surgery, and radiotherapy, is key for treating these childhood cancers.

Related Experiment Videos

Area of Science:

  • Pediatric Oncology
  • Urologic Oncology
  • Cancer Treatment Modalities

Context:

  • Urologic malignancies in children and adolescents include nephroblastomas, neuroblastomas, soft tissue sarcomas, and germ cell tumors.
  • Standard of care in Germany involves national and supranational treatment studies for pediatric cancers.

Purpose:

  • To outline the standard treatment approaches for pediatric urologic malignancies.
  • To highlight the efficacy of current treatment protocols and the principles of antineoplastic therapy.

Summary:

  • Nephroblastoma and germ cell tumors achieve nearly 90% 5-year survival rates.
  • Neuroblastoma and rhabdomyosarcoma show 60% 5-year survival rates across all stages.
  • Treatment principles align with adult oncology, with drug selection disease-dependent. Multimodal strategies involving chemotherapy, surgery, and radiotherapy are crucial.

Impact:

  • Establishes benchmarks for pediatric urologic cancer survival rates.
  • Informs treatment strategies for specific pediatric urologic cancers like nephroblastoma and neuroblastoma.
  • Emphasizes the importance of multimodal therapy in improving outcomes for childhood cancers.